AETHLON MEDICAL INC (AEMD) Form 8-K — Sep 17, 2026
$AEMDForm 8-KItems 1.01, 5.01, 7.01, 9.01Filed Sep 17, 2026, 8:03 AM ET0001683168-26-007206Original filing
Aethlon Medical entered into a merger agreement with North Immunology on September 17, 2026 under which two Aethlon merger subsidiaries will merge with North Immunology in a two-step reorganization intended to qualify as tax-free under Section 368(a). Upon closing, pre-merger North Immunology stockholders are expected to own approximately 95.25% of the combined company and existing Aethlon holders approximately 4.75%, with the company to be renamed North Immunology, Inc. and led by North Immunology's CEO.
Key figures
- Deal Value Usd
- $150,000,000 North Immunology equity value; $16,500,000 Aethlon valuation
- Outside date
- June 17, 2027
- Pipe aggregate
- approximately $180 million
- Maxim fee shares
- 591574
- Aethlon valuation
- $16,500,000 (reduced if net cash at closing is below $0)
- Pipe cash portion
- approximately $146 million
- Lockup period days
- 180
- Planned name change
- North Immunology, Inc.
- Pipe notes contribution
- approximately $34 million
- North immunology equity value
- $150,000,000
- Post merger ownership aethlon
- 4.75%
- Minimum pipe closing condition
- $175,000,000
- Termination fee payable by aethlon
- $300,000
- Post merger ownership north immunology
- 95.25%
- Beneficial ownership limitation default
- 9.99% (up to 19.99% at holder election)
- Termination fee payable by north immunology
- $2,000,000
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.